August 19, 2024Open Access

Overall Survival, Treatment Duration, and Rechallenge Outcomes With ICI Therapy for Recurrent or Metastatic HNSCC

Key Points

Key points are not available for this paper at this time.

Abstract

Immune checkpoint inhibition (ICI) is a frontline treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), but questions remain surrounding optimal duration of therapy, benefits and risks of ICI rechallenge, and efficacy in first vs subsequent lines of therapy.

Read Full Paperexternally

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Sun et al. (Mon,) studied this question.

synapsesocial.com/papers/68e5bb23b6db643587553269 https://doi.org/https://doi.org/10.1001/jamanetworkopen.2024.28526

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting2017 · 95 citations
2Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study2021 · 44 citations
3Untitled2021 · 6 citations
4Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck2016 · 5,082 citations
5Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer2020 · 582 citations

Demander à l'IA

Bookmark

View Full Paper